Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins.
Open accessThe DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Abstract
Dystrophin, the protein product of the Duchenne muscular dystrophy (DMD) gene, is absent in the skeletal muscle of DMD patients and mdx mice. At the plasma membrane of skeletal muscle fibers, dystrophin associates with a multimeric protein complex, termed the dystrophin-glycoprotein complex (DGC). Protein members of this complex are normally absent or greatly reduced in dystrophin-deficient skeletal muscle fibers, and are thought to undergo degradation through an unknown pathway. As such, we reasoned that inhibition of the proteasomal degradation pathway might rescue the expression and subcellular localization of dystrophin-associated proteins. To test this hypothesis, we treated mdx mice with the well-characterized proteasomal inhibitor MG-132. First, we locally injected MG-132 into the gastrocnemius muscle, and observed the outcome after 24 hours. Next, we performed systemic treatment using an osmotic pump that allowed us to deliver different concentrations of the proteasomal inhibitor, over an 8-day period. By immunofluorescence and Western blot analysis, we show that administration of the proteasomal inhibitor MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, beta-dystroglycan, alpha-dystroglycan, and alpha-sarcoglycan in skeletal muscle fibers from mdx mice. Furthermore, we show that systemic treatment with the proteasomal inhibitor 1) reduces muscle membrane damage, as revealed by vital staining (with Evans blue dye) of the diaphragm and gastrocnemius muscle isolated from treated mdx mice, and 2) ameliorates the histopathological signs of muscular dystrophy, as judged by hematoxylin and eosin staining of muscle biopsies taken from treated mdx mice. Thus, the current study opens new and important avenues in our understanding of the pathogenesis of DMD. Most importantly, these new findings may have clinical implications for the pharmacological treatment of patients with DMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“MG-132 also improves the dystrophic phenotype in a model of dystrophin deficiency (Bonuccelli et al., 2003; Winder et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as Bonuccelli et al., 2003
The cited source says what the claim attributes to it.
In the citing paper
“MG-132 also improved the dystrophic phenotype in a model of dystrophin deficiency (Bonuccelli et al., 2003; Winder et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as Bonuccelli et al., 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 1×
“For example, adenovirusmediated over-expression of these muscle-specific ubiquitin ligases produces muscle atrophy, whereas their genetic ablation resulted in resistance to muscle atrophy.(22) Previous studies from our laboratory(23) have demonstrated that proteasomal degradation may be involved in the pathogenesis of…”
BackgroundCaveolin, a protein component of caveolae membrane coats
Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y.-S., Glenney, J. R., & Anderson, R. G. W. (1992) · Cell · doi:10.1016/0092-8674(92)90143-z · Cited by 2,258
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“Intravenous injection of stem cells into lethally irradiated mdx mice resulted in the partial restoration of dystrophin expression in the affected muscle.(45) However, the complete suppression of the immune system remains a major problem.”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765 · cited 1×
“Research on DMD has greatly benefited from the availability of a naturally occurring mouse model, known as mdx, in which a non-sense mutation (premature stop codon) in the dystrophin gene ablates the expression of the dystrophin protein product.(8,9) The mdx mouse is viable and fertile, and exhibits histological lesio…”
BackgroundMembrane organization of the dystrophin-glycoprotein complex
Ervasti, J. M., & Campbell, K. P. (1991) · Cell · doi:10.1016/0092-8674(91)90035-w · Cited by 1,329
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276 · cited 1×
“Research on DMD has greatly benefited from the availability of a naturally occurring mouse model, known as mdx, in which a non-sense mutation (premature stop codon) in the dystrophin gene ablates the expression of the dystrophin protein product.(8,9) The mdx mouse is viable and fertile, and exhibits histological lesio…”
BackgroundProteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184 · cited 2×
“The discovery of many synthetic and natural inhibitors of the proteasomal pathway has been extremely useful in the comprehension of the mechanisms underlying intracellular protein degradation.(15) Most importantly, these new drugs may have very important in vivo applications, and may be instrumental in the pharmacolog…”
BackgroundCaveolins, Liquid-Ordered Domains, and Signal Transduction
Smart, E. J., Graf, G. A., McNiven, M. A., Sessa, W. C., Engelman, J. A., Scherer, P. E., Okamoto, T., & Lisanti, M. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7289 · Cited by 1,006
Self-citationBrenman, J. E., Chao, D. S., Xia, H., Aldape, K., & Bredt, D. S. (1995) · Cell · doi:10.1016/0092-8674(95)90471-9 · Cited by 961 · cited 1×
“The dystrophin complex also interacts with neuronal-type nitric oxide synthase (nNOS), whose biological product, NO, regulates contraction in skeletal muscle.(3,4) Another protein associated with the DGC, although not essential for the biogenesis of the complex itself, is caveolin-3 (Cav-3), a member of the caveolin p…”
Background
Cited by
Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0356-z · Cited by 880
Acharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M. L., Carathers, M., Li, Z.-W., Beg, A. A., Ghosh, S., Sahenk, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30556 · Cited by 438
“Similarly, though administration of nonspecific agents such as MG-132 (44) and, more recently, a synthetic antioxidant (45), has been shown to ameliorate the dystrophic phenotype, risks of inhibiting unwanted cellular targets can also sometimes outweigh the benefits (46).”
Mechanisms Regulating Neuromuscular Junction Development and Function and Causes of Muscle Wasting
Tintignac, L. A., Brenner, H.-R., & Rüegg, M. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00033.2014 · Cited by 422
“Consistent with the concept that inhibition of UPS affects muscle wasting, proteasome inhibitors, such as MG132, prevent muscle atrophy in rats and ameliorate the disease in mdx mice, the mouse model of Duchenne muscular dystrophy (50, 131, 421).”
BackgroundNowak, K. J., & Davies, K. E. (2004) · EMBO reports · doi:10.1038/sj.embor.7400221 · Cited by 357
Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies
Wallace, G. Q., & McNally, E. M. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163216 · Cited by 342
Metadata
- Authors
- Bonuccelli, G., Sotgia, F., Schubert, W., Park, D. S., Frank, P. G., Woodman, S. E., Insabato, L., Cammer, M., Minetti, C., & Lisanti, M. P.
- Affiliations
- Albert Einstein College of Medicine (US)
- University of Naples Federico II (IT)
- Istituto Giannina Gaslini (IT)
- Corresponding author
- Lisanti, Michael P.
- ORCID
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 163
- Issue
- 4
- Pages
- 1663-1675
- ISSN
- 0002-9440 (ISSN-L)
- PMC
- PMC1868305
- OpenAlex
- W2044961049
- Cited by
- 135
- References
- 48
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 1 · 2021: 3 · 2020: 9 · 2019: 5 · 2018: 5 · 2017: 5 · 2016: 2 · 2015: 7 · 2014: 6 · 2013: 9 · 2012: 4
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- Breast Cancer Alliance
- Muscular Dystrophy Association
- Ministero della Salute
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- Duchenne muscular dystrophy, dystrophin, mdx mice, proteasome inhibition, MG132, dystrophin-glycoprotein complex, beta-dystroglycan, alpha-dystroglycan, alpha-sarcoglycan, pharmacotherapy
- MeSH terms
- Animals, Cell Membrane, Cytoskeletal Proteins, Drug Administration Schedule, Infusion Pumps, Injections, Intramuscular, Injections, Subcutaneous, Leupeptins, Membrane Glycoproteins, Tissue Distribution, Cysteine Proteinase Inhibitors, Dystrophin, Mice, Inbred mdx, Muscle, Skeletal, Muscular Dystrophy, Duchenne, Dystroglycans, Sarcoglycans, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. https://app.cochat.ai/papers/10.1016/s0002-9440(10)63523-7
- The paper
- Bonuccelli, G., Sotgia, F., Schubert, W., Park, D. S., Frank, P. G., Woodman, S. E., Insabato, L., Cammer, M., Minetti, C., & Lisanti, M. P. (2003). Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. The American Journal of Pathology. https://doi.org/10.1016/s0002-9440(10)63523-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.